Chronic periaortitis (CP) usually responds to glucocorticoids, but some patients have glucocorticoid-refractory disease or contraindications to glucocorticoid therapy. This study was undertaken to evaluate treatment with the anti-interleukin-6 receptor (anti-IL-6R) antibody tocilizumab in 2 patients with CP, one with refractory disease and the other with contraindications to glucocorticoids, and to assess IL-6 levels in an additional cohort of patients with CP.
Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis / Vaglio, Augusto; Catanoso, Maria G; Spaggiari, Lucia; Magnani, Luca; Pipitone, Nicolò; Macchioni, Pierluigi; Pulsatelli, Lia; Nicastro, Maria; Becchi, Gabriella; Corradi, Domenico; Versari, Annibale; Boiardi, Luigi; Salvarani, Carlo. - In: ARTHRITIS AND RHEUMATISM. - ISSN 1529-0131. - 65:9(2013), pp. 2469-2475. [10.1002/art.38032]
Interleukin-6 as an inflammatory mediator and target of therapy in chronic periaortitis
SALVARANI, CARLO
2013
Abstract
Chronic periaortitis (CP) usually responds to glucocorticoids, but some patients have glucocorticoid-refractory disease or contraindications to glucocorticoid therapy. This study was undertaken to evaluate treatment with the anti-interleukin-6 receptor (anti-IL-6R) antibody tocilizumab in 2 patients with CP, one with refractory disease and the other with contraindications to glucocorticoids, and to assess IL-6 levels in an additional cohort of patients with CP.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
